Focusing on: The immune system in the brain, repurposed diabetes medications, and increasingly precise blood tests.
Microglia as Inflammation Modulators
Chronic inflammation is recognized as a key driver of neurodegenerative diseases. Microglia cells, integral components of the brain’s immune system, play a crucial role in regulating these processes. Esther Hellmann, a biotechnologist at IMC Krems, is investigating the TLR10 receptor, which could serve as an inflammation brake.
In the absence of this receptor, microglia exhibit changes in extracellular matrix and migratory behavior. Targeted modulation of such immune receptors may pave the way for new therapies against Alzheimer’s and Parkinson’s diseases. Furthermore, lifestyle factors like omega-3 fatty acids can modulate microglial activity, suggesting that both biology and lifestyle can influence cognitive health.
Diabetes Medications Significantly Reduce Alzheimer’s Risk
A cohort study from the National Institutes of Health (NIH) analyzed data from over 112,000 older adults collected between 2016-2024. Results show that certain diabetes medications considerably lower the risk of developing Alzheimer’s.
SGLT2 inhibitors reduced the risk by 43%, while GLP-1 agonists offered a 33% reduction. In participants with psychiatric predispositions, the risk reduction reached up to 46%. These findings bolster the theory that metabolic processes and glycemic control are crucial for maintaining cognitive health.
Advances in Early Detection
New blood tests for the protein p-Tau217 achieve over 90% accuracy, identifying pathological changes two to four years prior to the onset of clinical symptoms. Further research is utilizing 34 RNA markers in the blood, potentially allowing risk assessments up to 34 years in advance. Moreover, AI-assisted retinal scans promise to identify risks as much as 8.5 years before a clinical diagnosis.
The recent NIH study highlights the importance of SGLT2 inhibitors in lowering the Alzheimer’s risk for diabetics by 43%. Discover how to leverage these findings for your health in our free report, including a prevention checklist. Request your free report now
Emerging Drugs and New Forms of Cell Death
Since June 2026, antibody therapies like Lecanemab and Donanemab have been available in Germany, targeting the characteristic protein deposits associated with Alzheimer’s in the brain.
Additionally, a recently identified mechanism for cell death in Alzheimer’s, known as karyoptosis, has been documented in 35% of Alzheimer’s cells during a study involving 3,000 brain cells. This discovery opens new avenues for potential drugs targeting these pathways.
Risk Factors and Cautions on Supplements
Estimates suggest that around 45% of dementia cases can be traced back to 14 modifiable risk factors, including inadequate education, hearing loss, social isolation, and obesity. Programs integrating physical activity with cognitive exercises are considered effective in delaying symptoms.
Conversely, the unregulated intake of specific supplements raises concerns within the research community. A long-term study by the University of Florida (2012-2024) warns against glucosamine: for individuals with mild cognitive impairments, this supplement increased the Alzheimer’s risk by 25%. Claims regarding lithium for brain rejuvenation circulating on social media lack robust scientific backing. Experts view a case study on the use of psilocybin in an Alzheimer’s patient critically, citing methodological flaws and absence of control groups.
Non-Invasive Brain Stimulation as an Option
Transcranial pulse stimulation (TPS) has shown excellent compatibility in a study involving 785 patients, with no clinically relevant side effects. More than 100 clinics in the D-A-CH region already offer this procedure.
